De Novo Designed Hexadecapeptides Synergize Glycopeptide Antibiotics Vancomycin and Teicoplanin against Pathogenic Klebsiella pneumoniae via Disruption of Cell Permeability and Potential
- 14 February 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 3 (3) , 1738-1752
Abstract
Given the worldwide prevalence of pathogenic drug-resistant bacteria and the slow pace of new antibacterial development, discovering new uses for approved drugs that are outside the scope of the original indication is increasingly becoming an attractive proposition. In this work, seven linear cationic hexadecapeptides were designed, synthesized and characterized. These amphiphilic peptides are able to transform from the random coil structure in water to α-helix in SDS solution and have only modest bioactivity to limited bacterial strains when used alone. Surprisingly, one of them, namely zp16, was found to demonstrate significant synergy with vancomycin and teicoplanin against highly-pathogenic Klebsiella pneumoniae (KP) with FIC index as low as 0.03. Checkerboard assay indicated that in the presence of 8μM zp16, minimum inhibitory concentration (MIC) of vancomycin greatly was reduced from >128μM to 1μM to clinical-isolated carbapenem-resistant KP94. Additionally, the vancomycin-zp16 combination exhibited neglectable toxicity in vitro and in vivo. Further efficacy studies confirmed that the survival rate of combination therapy at 100mg/kg of zp16 and vancomycin was 30% higher than that of the single-drug treatment. More importantly, drug resistance has not developed to the combination even at the twentieth serial passage of KP1088. Mechanistic studies revealed that zp16 could strengthen the vancomycin’s influence on cell permeability and potential, leading to markedly reduced biofilm formation and rapid bactericidal effect. This new combination strategy expands the antibacterial spectrum of glycopeptide antibiotics and opens a new research direction for their application to treat pathogenic KP infection.Keywords
Funding Information
- Research Grants Council, University Grants Committee (15100115, 25100014 and C5026-16G)
- Innovation and Technology Commission
This publication has 70 references indexed in Scilit:
- Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitorEuropean Journal of Medicinal Chemistry, 2019
- Drug combinations: a strategy to extend the life of antibiotics in the 21st centuryNature Reviews Microbiology, 2019
- Prevalence and phenotypic characterization of carbapenem-resistant Klebsiella pneumoniae strains recovered from sputum and fecal samples of ICU patients in Zhejiang Province, ChinaInfection and Drug Resistance, 2018
- Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1European Journal of Medicinal Chemistry, 2018
- Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activityTuberculosis, 2018
- Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal ImplicationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Bisthiazolidines: A Substrate-Mimicking Scaffold as an Inhibitor of the NDM-1 CarbapenemaseACS Infectious Diseases, 2015
- Antisense Growth Inhibition of Methicillin-Resistant Staphylococcus aureus by Locked Nucleic Acid Conjugated with Cell-Penetrating Peptide as a Novel FtsZ InhibitorAntimicrobial Agents and Chemotherapy, 2015
- Diaryl‐Substituted Azolylthioacetamides: Inhibitor Discovery of New Delhi Metallo‐β‐Lactamase‐1 (NDM‐1)ChemMedChem, 2014
- Silver as Antibacterial Agent: Ion, Nanoparticle, and MetalAngewandte Chemie International Edition, 2012